The efficacy and safety of golimumab in the treatment of arthritis

Expert Opinion on Biological Therapy

Volumn 10, Issue 7, 2010, Pages 1131-1143

  Fleischmann, Roy ^a,b  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; Biologic therapy; Golimumab; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SIMPONI; TOCILIZUMAB; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BASAL CELL CARCINOMA; BREAST CANCER; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SPECIFICITY; HODGKIN DISEASE; HUMAN; LIP CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; OPPORTUNISTIC INFECTION; POSTMARKETING SURVEILLANCE; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; STEADY STATE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS SPONDYLITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953346133     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.493873     Document Type: Review

References (92)

1. Helmick C, Felson D, Lawrence R, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008;58:15-25
2. MacGregor AJ, Silman AJ. Classification and epidemiology. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors, Rheumatology. 3rd edition. Elsevier Science, Phildelphia PA, USA; 2003. p. 757-763
3. Albers JM, Kuper HH, Van Riel PL, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999;38:423-430
4. Habib G, Artul S, Ratson N, Froom P. Household work disability of Arab housewives with rheumatoid arthritis. Clin Rheumatol 2007;26:759-763
5. Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 2009;38:320-335
6. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 2009;36:1012-1020
7. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 2009;26:1681-1685
8. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, et al. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol 1998;37:848-853
9. Wallenius M, Skomsvoll JF, Koldingsnes W, et al. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009;68:685-689
10. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives?. Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000;39:603-611
11. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis?. Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335-340
12. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42:588-596
13. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-855
14. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8:S49-S60
15. Olivieri I, Mantovani LG, D'Angelo S, et al. Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep 2009;11:263-269
16. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol: 2005;32:1875-1883
17. Dunlop DD, Manheim LM, Yelin EH, et al. The costs of arthritis. Arthitis Rheum 2003;49:101-113
18. Aletaha D, Eberl G, Nell VP, et al. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004;63:1269-1275
19. Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2009;21:324-334
20. Breedveld FC. Should rheumatoid arthritis be treated conservatively or aggressively? Rheumatology (Oxford) 2003;42(Suppl 2):ii41-ii43
21. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-947
22. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-269
23. Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 2009;21:348-355
24. Olivieri I, D'Angelo S, Palazzi C, Padula A. Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother 2009;10:271-282
25. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003;21:S209-S21
26. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-266
27. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-2550
28. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822
29. Weinblatt ME, Polisson R, Blotner SD, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-619
30. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
31. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563
32. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-516
33. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486
34. Fleischmann R, Vencovsky J, van VR, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2008;68:805-811
35. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103-1111
36. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581 (Pubitemid 38758544)
37. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-624
38. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
39. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876
40. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602
41. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804
42. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259
43. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
44. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593
45. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-382
46. Klareskog L, van der Heijde DM, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-681
47. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443
48. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-1877
49. Van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35(Suppl 2):4-7
50. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-793
51. van der Heijde DM, Van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-1038
52. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236
53. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-2146
54. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127
55. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450-1453
56. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-1278
57. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-876
58. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-2259
59. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-1043
60. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65:471-477
61. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-2707 (Pubitemid 47237288)
62. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-390
63. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-721
64. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66:163-168
65. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-3289
66. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-709
67. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
68. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123
69. Hyrich K, Lunt M, Watson K, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthitis Rheum 2007;56:13-20
70. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-1714
71. van Vollenhoven RF, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-1198
72. Golimumab Product Information. Centocor, Malvern PA; 2009
73. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-396
74. Adalimumab Product Information. Abbott, Abbott Park, IL; 2010
75. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-2283
76. Emery P, Fleischmann R, van der Heijde D, et al. Golimumab and radiographic progression in rheumatoid arthritis: results of GO-BEFORE and GO-FORWARD Studies [abstract 640] Arthitis Rheum 2009;60
77. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-740
78. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-796
79. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-221
80. Van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthitis Rheum 1984;27:361-368
81. Garrett S, Jenkinson T, Kennedy L, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-2291
82. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum 2008;58:3402-3412
83. Anderson JJ, Baron G, van der Heijde DM, et al. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthitis Rheum 2001;44:1876-1886
84. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-2285
85. Jenkinson T, Mallorie P, Whitelock H. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694-1698
86. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-986
87. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-244
88. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-212
89. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-928
90. Genovese MC, Keystone E, Hsia EC, et al. Golimumab significantly improves physical function, health-related quality of life, and fatigue in RA patients: results from the GO-FORWARD Study [abstract 1040]. Arthitis Rheum 2008;58
91. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-975
92. Fleischmann R. Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? Rheum Dis Clin North Am 2006, 1:2-9